IL-23p19 agents in Ulcerative Colitis Expert Video April 7, 2025 ~ Robert Battat, MD***Post-Survey & Application for CME Credit***

In order to receive credit for this activity, you must read the front matter, view the activity, complete the post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.

2.What is your community of practice?

Academic

Community

Industry

Other (please specify)

3.Patient with moderate to severe ulcerative colitis, initially treated with IFX now losing response despite adequate therapeutic drug level.

Which therapy/MOA is as effective in bio-exposed patients as it is in bio-naïve patients in the RCT that led to drug approval?(Required.)

Adalimumab

Vedolizumab

Mirikizumab, Guselkumab

None of the above

4.At week 52 what is the percentage of patients treated with Mirikizumab for moderate to severe UC who achieved endoscopic improvement defined as an endoscopic Mayo score of 0 or 1 without friability (extra-point: delta Miri vs placebo induction)?(Required.)

38% (delta 7)

48 % (delta 17)

58% (delta 27)

EVALUATION FORM

5.Upon completion of this activity, I am able to:

Strongly agree

Agree

Disagree

Strongly disagree

Evaluate the clinical safety and efficacy data for newly approved and emerging therapies for patients with IBD

Strongly agree

Agree

Disagree

Strongly disagree

6.Please indicate the extent of your agreement with the following statements:

Strongly agree

Agree

Disagree

Strongly disagree

The faculty for this activity were effective

Strongly agree

Agree

Disagree

Strongly disagree

7.Overall, was this activity fair, balanced and free from commercial bias?

Yes

No

8.If no, please explain:

9.Of the patients with IBD you will see in the next month, about how many will benefit from the information you learned today?

1 to 10

11 to 25

26 to 50

I am not directly involved in patient care

10.Based on what I learned today, I will improve my practice by incorporating the following for my patients with IBD (check all that apply):

Consider anti-IL23p19 therapies for patients

Utilize the latest efficacy data to make evidence-based decisions when selecting between IL-23 therapies

Individualize treatment selection for patients with UC and Crohn's

I do not plan on making changes to my practice at this time

Other (explain)

11.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Lack of knowledge regarding anti-IL23p19 subunits (provider-related barrier)

Challenges applying frequency and quantity of new data into practice (provider-related barrier)

Lack of time resources to consider change (practice-related barrier)

Inadequate support staff for pt education/insurance/billing/administrative issues (practice-level barrier)

Limited access to novel therapies (systems-level barrier)

Insurance reimbursement or legal issues (systems-related barrier)

Other (please specify)

12.For purposes of certification, you must complete the following information.
*Please note that we will not forward or sell your contact information.*(Required.)

First Name

Last Name

Degree/Credentials:

City

State/Province

ZIP/Postal Code

Country

Email Address (required to receive credit)

13.I certify that I have participated in the continuing education activity entitled, "MondayNightIBD | IL-23p19 agents in Ulcerative Colitis Expert Video" and claim 0.5 AMA PRA Category 1 Credit^TM.(Required.)

Yes

No

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com